A new iud insertion technique utilizing cervical priming with prostaglandin

Area of Science:

• Reproductive medicine
• Gynecology

Background:

• Intrauterine device (IUD) insertion can be challenging due to cervical rigidity.
• Cervical priming aims to facilitate IUD insertion by softening and dilating the cervix.

Purpose of the Study:

• To evaluate the efficacy of a 15(S)-15-methyl prostaglandin F2a (15-ME-PGF2a) vaginal suppository for cervical priming before IUD insertion.
• To assess the impact of cervical priming on cervical dilatation, ease of IUD insertion, and patient tolerance.

Main Methods:

• A single 0.5 mg 15-ME-PGF2a vaginal suppository was administered one hour prior to IUD insertion.
• IUD insertions were performed between 7 to 17 days post-LMP, with exceptions for prolonged amenorrhea.
• Cervical dilatation and procedural outcomes were recorded.

Main Results:

• A mean increase in cervical dilatation of 2.14 mm was observed.
• The prostaglandin suppository facilitated IUD insertion and expanded the potential insertion time frame.
• The method was well tolerated, with minimal side effects and elimination of nausea and syncope.

Conclusions:

• 15-ME-PGF2a vaginal suppositories are effective for cervical priming, improving IUD insertion outcomes.
• This method enhances cervical ripening and dilatation, leading to a simpler and more comfortable procedure.
• Prostaglandin-induced cervical priming offers a safe and well-tolerated approach to facilitate IUD insertion.